Core Viewpoint - Rongjie Health Technology Co., Ltd. plans to engage in financial derivatives trading to mitigate foreign exchange risk associated with its export business, primarily settled in USD [1][2]. Summary by Sections Trading Overview - The company aims to conduct financial derivatives trading to hedge against foreign exchange fluctuations and reduce financial costs, focusing on non-speculative operations [1]. - The trading will involve currencies aligned with the company's primary settlement currency, including forward foreign exchange, foreign exchange swaps, currency swaps, foreign exchange options, and other financial derivatives [1]. - The trading limit is set at a maximum of RMB 100 million (or equivalent foreign currency), valid for 12 months from board approval, and can be reused [1]. Approval Process - The proposal for financial derivatives trading was approved by the company's board of directors on August 25, 2025, and does not require shareholder meeting approval [2]. Risk Analysis - The company acknowledges potential risks, including foreign exchange volatility, internal control weaknesses, liquidity issues, and legal risks associated with changes in laws or counterparty defaults [2]. - To mitigate these risks, the company has established a management system for financial derivatives trading, ensuring careful contract review and adherence to risk management protocols [2]. Impact on the Company - Engaging in financial derivatives trading is expected to help the company avoid foreign exchange market risks, lower financial costs, and enhance foreign exchange gains without adversely affecting its financial and operational status [3]. - The company will account for these transactions according to relevant accounting standards, with specific outcomes subject to audit [3].
融捷健康拟斥资不超1亿元开展金融衍生品交易业务